Biotech Values

[ghmm]

BMY / CTMX:

Don't know if this is news but apparently there is a second CTLA-4 program in the collaboration

http://ir.cytomx.com/phoenix.zhtml?c=254195&p=irol-newsArticle&ID=2315188

Bristol-Myers Squibb (BMS) Partnership

. BMS continues to advance its CTLA-4-directed Probody therapeutic, which is expected to enter the clinic in early 2018.
. In addition, CytomX and Bristol-Myers Squibb are evaluating a Probody version of Bristol-Myers Squibb's CTLA-4 nonfucosylated (CLTA-4-NF) version of ipilimumab as part of the current collaboration.

Had to google nonfucosylated never heard that before!